Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
58 hedge funds and large institutions have $79.7M invested in Tourmaline Bio in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
57% more capital invested
Capital invested by funds: $50.6M → $79.7M (+$29.1M)
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
7% more funds holding
Funds holding: 54 → 58 (+4)
2.74% less ownership
Funds ownership: 64.55% → 61.81% (-2.7%)
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$5.96M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.31M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.7M |
| 5 |
QF
QVT Financial
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$6.18M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.93M |
| 3 |
BlackRock
New York
|
-$2.64M |
| 4 |
Citigroup
New York
|
-$2.17M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.12M |
TRML Hedge Fund Activity: Q2 2023 in Review
58 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q2 2023, worth a combined $79.7M — up 57% from $50.6M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TRML positions and 16 closed out — a net gain of 4 holders — while 11 added to existing stakes and 20 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $5.96M. The largest seller was Viking Global Investors, exiting entirely with an estimated $6.18M sold.
- 58 institutional investors held Tourmaline Bio (TRML) as of Q2 2023, up from 54 in Q1 2023.
- Funds reported $79.7M of Tourmaline Bio stock for Q2 2023, up 57% quarter-over-quarter.
- 20 funds opened new Tourmaline Bio positions in Q2 2023 and 16 closed out, a net change of +4 holders.
- The largest Tourmaline Bio buyer in Q2 2023 was RA Capital Management, an estimated $5.96M added.
- The largest Tourmaline Bio seller in Q2 2023 was Viking Global Investors, an estimated $6.18M sold.
Based on aggregated 13F filings for Q2 2023.